All In Biotech

NDA 209575 · Omnivium Pharms

Numbrino

Cocaine Hydrochloride · Nasal

Last checked: Nov 20, 2026Latest source record: Aug 27, 2020 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2020

Jan 10, 2020

Approved uses

1

Original approval plus efficacy supplements

Registered trials

415

35 Phase 3, 16 recruiting

FAERS reports

65

64 serious, 7 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

Boxed warning

WARNING: ABUSE AND DEPENDENCE CNS stimulants, including cocaine hydrochloride, have a high potential for abuse and dependence. ( 5.1 ) WARNING: ABUSE AND DEPENDENCE See full prescribing information for complete boxed warning. CNS stimulants, including cocaine hydrochloride, have a high potential for abuse and dependence. ( 5.1 )

What it is approved for

From the label in effect Jan 12, 2026.

NUMBRINO (cocaine hydrochloride) nasal solution is indicated for the induction of local anesthesia of the mucous membranes when performing diagnostic procedures and surgeries on or through the nasal cavities in adults. NUMBRINO (cocaine hydrochloride) nasal solution is an ester local anesthetic indicated for the introduction of local anesthesia of the mucous membranes for diagnostic procedures and surgeries on or through the nasal cavities of adults. ( 1 )

Mechanism: Cocaine hydrochloride is a local anesthetic of the ester type. Cocaine hydrochloride prevents conduction in nerve fibers by reversibly blocking voltage-gated sodium channels and preventing the transient rise in sodium conductance necessary for generation of an action potential.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Jan 10, 2020 Original approval · Type 7 - Drug Already Marketed without Approved NDA LetterLabelReview
1 products under this application
  • NUMBRINO · COCAINE HYDROCHLORIDE 4% · SOLUTION, NASAL · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Cocaine" as an intervention, any sponsor and status, largest first.

All 415 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • drug abuse28
  • toxicity to various agents26
  • acute kidney injury11
  • multiple organ dysfunction syndrome8
  • rhabdomyolysis6
  • cardiac arrest5
  • cardiomyopathy5
  • overdose5
  • drug interaction4
  • metabolic acidosis4
  • pneumonia4
  • substance abuse4

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20211
20221
20236
202412
202514
202631

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 2,398 on PubMed

Sponsor: Omnivium Pharms

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.